Global Retirement Partners LLC Has $663,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Global Retirement Partners LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 631 shares of the biopharmaceutical company’s stock after acquiring an additional 193 shares during the period. Global Retirement Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $663,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Good Life Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 60.0% during the 3rd quarter. Good Life Advisors LLC now owns 384 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 144 shares during the last quarter. Greater Midwest Financial Group LLC boosted its holdings in Regeneron Pharmaceuticals by 0.7% in the 3rd quarter. Greater Midwest Financial Group LLC now owns 2,520 shares of the biopharmaceutical company’s stock worth $2,649,000 after buying an additional 18 shares during the period. Tamar Securities LLC boosted its holdings in Regeneron Pharmaceuticals by 16.6% in the 3rd quarter. Tamar Securities LLC now owns 15,492 shares of the biopharmaceutical company’s stock worth $16,286,000 after buying an additional 2,211 shares during the period. Bfsg LLC boosted its holdings in Regeneron Pharmaceuticals by 3,352.0% in the 3rd quarter. Bfsg LLC now owns 863 shares of the biopharmaceutical company’s stock worth $907,000 after buying an additional 838 shares during the period. Finally, Transform Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 7.5% in the 3rd quarter. Transform Wealth LLC now owns 9,729 shares of the biopharmaceutical company’s stock worth $10,228,000 after buying an additional 677 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $990.68 on Monday. The firm has a market capitalization of $109.16 billion, a P/E ratio of 29.27, a PEG ratio of 3.45 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company’s fifty day moving average is $1,109.58 and its two-hundred day moving average is $1,041.01.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.79 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

REGN has been the subject of several analyst reports. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,116.00.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.